



Michael R. Pence, Governor
State of Indiana

Indiana Family and Social Services Administration

402 W. WASHINGTON STREET, P.O. BOX 7083
INDIANAPOLIS, IN 46207-7083

John J. Wernert, M.D., Secretary

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

August 5, 2016

1:00 P.M.

Conference Center Room "A"

Indiana State Government Center South

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review - Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
 - a. Respiratory
 - i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
 - ii. Antiviral Monoclonal Antibodies
 - iii. Beta Adrenergics and Corticosteroids
 - iv. Beta Agonists
 - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
 - vi. Leukotriene Receptor Antagonists
 - vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
 - viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
 - ix. Oral Inhaled Glucocorticoids
 - x. Phosphodiesterase-4 Inhibitors
 - xi. Pulmonary Antihypertensives



b. Anti-Infectives

- i. Antivirals - Anti-Herpetic Agents
- ii. Antivirals - Influenza Agents
- iii. Cephalosporins - 3rd Generation
- iv. Fluoroquinolones
- v. Hepatitis C Agents
- vi. Ketolides
- vii. Macrolides
- viii. Ophthalmic Antibiotics
- ix. Ophthalmic Antibiotics/Corticosteroid Combinations
- x. Oral Non-Systemic Antifungals
- xi. Otic Antibiotics
- xii. Systemic Antifungals
- xiii. Topical Antifungals
- xiv. Topical Antivirals
- xv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
- xvi. Vaginal Antimicrobials

c. Cardiovascular

- i. Angiotensin-Converting Enzyme (ACE) Inhibitors
- ii. ACE Inhibitors in combination with Calcium Channel Blockers (CCBs)
- iii. ACE Inhibitors in combination with Diuretics
- iv. Alpha Adrenergic Blockers
- v. Alpha/Beta Adrenergic Blockers
- vi. Angiotensin II Receptor Antagonists (ARBs)
- vii. ARBs in combination with CCBs
- viii. ARBs in combination with CCBs and Diuretics
- ix. ARBs in combination with Diuretics
- x. Beta Adrenergic Blockers
- xi. Beta Adrenergic Blockers with Diuretics
- xii. Calcium Channel Blockers

- xiii. CCBs with HMG-CoA Reductase Inhibitors
- xiv. Direct Renin Inhibitors
- xv. Direct Renin Inhibitors in combination with CCBs
- xvi. Direct Renin Inhibitors in combination with CCBs and Diuretics
- xvii. Direct Renin Inhibitors in combination with Diuretics
- xviii. Miscellaneous Cardiac Agents
- d. Lipotropics
 - i. Bile Acid Sequestrants
 - ii. Fibrin Acid Derivatives
 - iii. HMG-CoA Reductase Inhibitors
 - iv. Lipotropics
- e. Antimigraine Agents
- f. Electrolyte Depleters
- g. Multiple Sclerosis Agents
- h. CNS and Others
 - i. Narcotics
- 4. Public Comment
- 5. Other Business
- 6. Adjourn